Olanzapine/samidorphan explained
| Type: | combo |
| Component1: | Olanzapine |
| Class1: | Atypical antipsychotic |
| Component2: | Samidorphan |
| Class2: | Opioid antagonist |
| Tradename: | Lybalvi |
| Dailymedid: | Olanzapine and samidorphan |
| Routes Of Administration: | By mouth |
| Atc Prefix: | N05 |
| Atc Suffix: | AH53 |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Kegg: | D12117 |
| Synonyms: | ALKS-3831; OLZ/SAM |
Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder. It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist.[2] [3] Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect.[4] [5] The formulation was approved for medical use in the United States in May 2021.[6]
Notes and References
- Web site: Lybalvi- olanzapine and samidorphan l-malate tablet, film coated . DailyMed . 24 February 2022 . 1 May 2023.
- Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C . Improving Current Treatments for Schizophrenia . Drug Development Research . 77 . 7 . 357–367 . 2016 . 27633376 . 10.1002/ddr.21337 . 205750190 .
- Fellner C . New Schizophrenia Treatments Address Unmet Clinical Needs . P T . 42 . 2 . 130–134 . 2017 . 28163559 . 5265239 .
- Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, DiPetrillo L, Cummings H, Sun L, McDonnell D . 6 . An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder . Neuropsychiatr Dis Treat . 17 . 2885–2904 . 2021 . 34526769 . 8437420 . 10.2147/NDT.S313840 . free .
- Paik J . Olanzapine/Samidorphan: First Approval . Drugs . 81 . 12 . 1431–1436 . August 2021 . 34304374 . 10.1007/s40265-021-01568-0 . 236215923 .
- Web site: Drug Approval Package: Lybalvi . U.S. Food and Drug Administration (FDA) . 26 June 2021 . 12 September 2021.
